<DOC>
	<DOC>NCT02307370</DOC>
	<brief_summary>The primary objective for this study is to prove the safety and effectiveness of the Spectranetics Turbo-Elite catheter in atherectomy treatment for infrainguinal arteries with catheter to vessel sizing of at least 50%.</brief_summary>
	<brief_title>Atherectomy By Laser Ablation With Turbo-Elite</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>PAD with Rutherford Class 14 Patient is able to walk unassisted or with nonmotorized assistive devices. Documented PAD by ABI &lt;0.9 or previous intervention with reoccurrence of symptoms Documented stenosis by duplex ≥50% Patient is pregnant or breast feeding. Evidence of Acute Limb Ischemia within 7 days prior to procedure. CVA &lt; 60 days prior to procedure. MI &lt; 60 days prior to procedure. Known contraindication to aspirin, antiplatelet/anticoagulant therapies required for procedure/follow up. Known allergy to contrast media that cannot adequately be premedicated prior to study procedure. Uncontrolled hypercoagulability or history of HIT or HITTS syndrome. Serum creatinine ≥ 2.5 mg/dL (unless dialysisdependent) within one day prior to procedure. Patient is simultaneously participating in another investigational drug or device study that will interfere with the 30 day Safety Endpoint. Previously identified severe calcium in the vessel.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>